FutureTox IV Workshop Summary: Predictive Toxicology for Healthy Children.

in silico modeling children’s environmental health developmental and reproductive toxicity testing high-throughput screening in vitro profiling new approach methodologies (NAMs) pediatric health

Journal

Toxicological sciences : an official journal of the Society of Toxicology
ISSN: 1096-0929
Titre abrégé: Toxicol Sci
Pays: United States
ID NLM: 9805461

Informations de publication

Date de publication:
12 04 2021
Historique:
pubmed: 9 2 2021
medline: 19 8 2021
entrez: 8 2 2021
Statut: ppublish

Résumé

FutureTox IV, a Society of Toxicology Contemporary Concepts in Toxicology workshop, was held in November 2018. Building upon FutureTox I, II, and III, this conference focused on the latest science and technology for in vitro profiling and in silico modeling as it relates to predictive developmental and reproductive toxicity (DART). Publicly available high-throughput screening data sets are now available for broad in vitro profiling of bioactivities across large inventories of chemicals. Coupling this vast amount of mechanistic data with a deeper understanding of molecular embryology and post-natal development lays the groundwork for using new approach methodologies (NAMs) to evaluate chemical toxicity, drug efficacy, and safety assessment for embryo-fetal development. NAM is a term recently adopted in reference to any technology, methodology, approach, or combination thereof that can be used to provide information on chemical hazard and risk assessment to avoid the use of intact animals (U.S. Environmental Protection Agency [EPA], Strategic plan to promote the development and implementation of alternative test methods within the tsca program, 2018, https://www.epa.gov/sites/production/files/2018-06/documents/epa_alt_strat_plan_6-20-18_clean_final.pdf). There are challenges to implementing NAMs to evaluate chemicals for developmental toxicity compared with adult toxicity. This forum article reviews the 2018 workshop activities, highlighting challenges and opportunities for applying NAMs for adverse pregnancy outcomes (eg, preterm labor, malformations, low birth weight) as well as disorders manifesting postnatally (eg, neurodevelopmental impairment, breast cancer, cardiovascular disease, fertility). DART is an important concern for different regulatory statutes and test guidelines. Leveraging advancements in such approaches and the accompanying efficiencies to detecting potential hazards to human development are the unifying concepts toward implementing NAMs in DART testing. Although use of NAMs for higher level regulatory decision making is still on the horizon, the conference highlighted novel testing platforms and computational models that cover multiple levels of biological organization, with the unique temporal dynamics of embryonic development, and novel approaches for estimating toxicokinetic parameters essential in supporting in vitro to in vivo extrapolation.

Identifiants

pubmed: 33555348
pii: 6129273
doi: 10.1093/toxsci/kfab013
pmc: PMC8041457
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

198-211

Subventions

Organisme : NIEHS NIH HHS
ID : P30 ES007033
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES017885
Pays : United States

Informations de copyright

Published by Oxford University Press on behalf of the Society of Toxicology 2021.

Références

Environ Health Perspect. 2018 Jul 24;126(7):077009
pubmed: 30044231
Regul Toxicol Pharmacol. 2014 Dec;70(3):629-40
pubmed: 25261300
Cell Rep. 2018 May 22;23(8):2392-2404
pubmed: 29791850
Arch Toxicol. 2015 Feb;89(2):269-87
pubmed: 25618548
Methods Mol Biol. 2013;947:223-31
pubmed: 23138908
Arch Toxicol. 2017 Apr;91(4):2017-2028
pubmed: 27722930
Chem Res Toxicol. 2019 Apr 15;32(4):536-547
pubmed: 30907586
Reprod Toxicol. 2016 Sep;64:151-61
pubmed: 27180093
Mol Neurobiol. 2020 Jan;57(1):200-207
pubmed: 31578707
Fertil Steril. 2016 Sep 15;106(4):905-29
pubmed: 27513554
Science. 2014 Feb 14;343(6172):791-795
pubmed: 24407478
Curr Opin Pharmacol. 2014 Dec;19:125-33
pubmed: 25306433
Toxicol Sci. 2018 Sep 1;165(1):198-212
pubmed: 30007363
Environ Health Perspect. 2016 Jul;124(7):1023-33
pubmed: 26908244
Exp Biol Med (Maywood). 2017 Oct;242(16):1559-1572
pubmed: 29065799
Toxicol Sci. 2018 May 1;163(1):279-292
pubmed: 29462422
J Adolesc Health. 2009 Sep;45(3):216-21
pubmed: 19699416
Scand J Clin Lab Invest Suppl. 2012;243:7-13
pubmed: 22536757
J Natl Cancer Inst. 2019 Aug 1;111(8):803-810
pubmed: 30759253
Lab Chip. 2012 Nov 7;12(21):4560-8
pubmed: 22964798
Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18347-18356
pubmed: 31451641
Chem Res Toxicol. 2014 Mar 17;27(3):314-29
pubmed: 24446777
Nat Rev Endocrinol. 2020 Jan;16(1):45-57
pubmed: 31719706
Environ Health Perspect. 2020 Feb;128(2):27002
pubmed: 32074470
Reprod Toxicol. 2017 Jun;70:60-69
pubmed: 27838387
ALTEX. 2017;34(3):362-376
pubmed: 27883356
Chem Res Toxicol. 2017 Apr 17;30(4):965-979
pubmed: 28045533
Toxicol Sci. 2018 Dec 01;166(2):394-408
pubmed: 30496568
Toxicol Sci. 2014 Dec;142(2):312-20
pubmed: 25466378
Toxicol Sci. 2014 Nov;142(1):210-24
pubmed: 25145659
Birth Defects Res. 2018 Jun 1;110(10):840-850
pubmed: 29436169
Toxicol Sci. 2015 Nov;148(1):121-36
pubmed: 26251325
Toxicol Sci. 2020 Jan 1;173(1):202-225
pubmed: 31532525
Toxicol Sci. 2017 Jan;155(1):22-31
pubmed: 27780885
Birth Defects Res. 2020 Jan 1;112(1):19-39
pubmed: 31471948
Reprod Toxicol. 2020 Apr;93:250-258
pubmed: 32171711
Am J Psychiatry. 1999 Jan;156(1):4
pubmed: 9892290
PLoS One. 2013 Jul 09;8(7):e68708
pubmed: 23874735
Stem Cell Reports. 2015 Apr 14;4(4):632-44
pubmed: 25843047
Pediatrics. 2011 Jun;127(6):1034-42
pubmed: 21606152
Environ Health Perspect. 2004 Feb;112(2):238-56
pubmed: 14754580
Elife. 2018 Aug 01;7:
pubmed: 30067223
Dis Model Mech. 2019 Aug 6;12(8):
pubmed: 31413047
Development. 2019 Jul 4;146(13):
pubmed: 31273085
Environ Sci Technol. 2015 Jul 21;49(14):8804-14
pubmed: 26066997
Elife. 2018 Oct 29;7:
pubmed: 30371350
MMWR Surveill Summ. 2020 Mar 27;69(4):1-12
pubmed: 32214087
Exp Biol Med (Maywood). 2017 Oct;242(16):1586-1592
pubmed: 28658972
Reprod Toxicol. 2015 Dec;58:149-59
pubmed: 26472102
Environ Health Perspect. 2013 Jun;121(6):717-24
pubmed: 23603051
Dev Growth Differ. 2007 May;49(4):265-75
pubmed: 17501904
Science. 2008 Feb 15;319(5865):906-7
pubmed: 18276874
Regul Toxicol Pharmacol. 2020 Jul;114:104668
pubmed: 32335207
J Clin Pharmacol. 2018 Jul;58(7):885-890
pubmed: 29663424
Front Cell Neurosci. 2020 Feb 21;14:25
pubmed: 32153365
EFSA J. 2018 Jun 07;16(6):e05311
pubmed: 32625944
Chem Res Toxicol. 2013 Dec 16;26(12):1840-61
pubmed: 24206190
Curr Protoc Toxicol. 2013 Feb;Chapter 16:Unit 16.10
pubmed: 23408194
J Matern Fetal Neonatal Med. 2016;29(7):1046-54
pubmed: 26075842
Toxicol Appl Pharmacol. 2019 Oct 15;381:114714
pubmed: 31437492
Clin Pharmacol Ther. 2015 Sep;98(3):245-51
pubmed: 25963725
J Stat Softw. 2017 Jul 17;79(4):1-26
pubmed: 30220889
Pharmacol Ther. 2016 Sep;165:79-92
pubmed: 27218886
PLoS Comput Biol. 2013 Apr;9(4):e1002996
pubmed: 23592958
Curr Neurol Neurosci Rep. 2019 May 28;19(7):38
pubmed: 31139952
Toxicol Sci. 2014 Feb;137(2):269-77
pubmed: 24204016
Nat Commun. 2017 Mar 28;8:14584
pubmed: 28350383
Toxicol Sci. 2015 Feb;143(2):256-67
pubmed: 25628403
Environ Health Perspect. 2011 Jun;119(6):878-85
pubmed: 21233055
WormBook. 2006 Jan 24;:1-14
pubmed: 18050477
Toxicol Sci. 2019 Jun 1;169(2):317-332
pubmed: 30835285
PLoS Comput Biol. 2019 Mar 28;15(3):e1006577
pubmed: 30921323
Methods Mol Biol. 2016;1473:99-107
pubmed: 27518628
PLoS Biol. 2019 Aug 29;17(8):e3000372
pubmed: 31465433
ALTEX. 2014;31(1):63-78
pubmed: 24114257
Front Public Health. 2018 Jul 10;6:185
pubmed: 30042936

Auteurs

Thomas B Knudsen (TB)

U.S. Environmental Protection Agency, ORD, Research Triangle Park, North Carolina, USA.

Suzanne Compton Fitzpatrick (SC)

US Food and Drug Administration, College Park, Maryland, USA.

K Nadira De Abrew (KN)

The Procter and Gamble Company, Cincinnati, Ohio, USA.

Linda S Birnbaum (LS)

National Institute of Environmental Health Science, NIH, Research Triangle Park, North Carolina, USA.

Anne Chappelle (A)

Chappelle Toxicology Consulting, LLC, Chadds Ford, Pennsylvania, USA.

George P Daston (GP)

The Procter and Gamble Company, Cincinnati, Ohio, USA.

Dana C Dolinoy (DC)

University of Michigan, Ann Arbor, Michigan, USA.

Alison Elder (A)

University of Rochester, Rochester, New York, USA.

Susan Euling (S)

U.S. Environmental Protection Agency, Office of Children's Health Protection, Washington, District of Columbia, USA.

Elaine M Faustman (EM)

University of Washington, Seattle, Washington, USA.

Kristi Pullen Fedinick (KP)

Natural Resources Defense Council, Washington, District of Columbia, USA.

Jill A Franzosa (JA)

U.S. Environmental Protection Agency, ORD, Research Triangle Park, North Carolina, USA.

Derik E Haggard (DE)

U.S. Environmental Protection Agency, ORD, Research Triangle Park, North Carolina, USA.
Oak Ridge Institute for Science and Education (ORISE);, Texas, USA.

Laurie Haws (L)

ToxStrategies, Inc., Austin, Texas, USA.

Nicole C Kleinstreuer (NC)

National Toxicology Program, NIEHS, Durham, North Carolina, USA.

Germaine M Buck Louis (GM)

George Mason University, Fairfax, Virginia, USA.

Donna L Mendrick (DL)

U.S. Food and Drug Administration, NCTR, Silver Spring, Maryland, USA.

Ruthann Rudel (R)

Silent Spring Institute, Newton, Massachusetts, USA.

Katerine S Saili (KS)

U.S. Environmental Protection Agency, ORD, Research Triangle Park, North Carolina, USA.

Thaddeus T Schug (TT)

National Institute of Environmental Health Science, NIH, Research Triangle Park, North Carolina, USA.

Robyn L Tanguay (RL)

Oregon State University, Corvallis, Oregon, USA.

Alexandra E Turley (AE)

US Food and Drug Administration, College Park, Maryland, USA.

Barbara A Wetmore (BA)

U.S. Environmental Protection Agency, ORD, Research Triangle Park, North Carolina, USA.

Kimberly W White (KW)

American Chemistry Council, Washington, District of Columbia, USA.

Todd J Zurlinden (TJ)

U.S. Environmental Protection Agency, ORD, Research Triangle Park, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH